10 likes | 31 Vues
According to DelveInsight, the market size of Pulmonary Arterial Hypertension in 7MM was found to be USD 4.6 Billion in 2017.<br><br>Among the 7MM, the United States accounts for the largest market size of Pulmonary Arterial Hypertension, in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.<br><br>The total number of prevalent cases of Pulmonary Arterial Hypertension (PAH) in 7MM was found to be 70,774, in the year 2017.<br><br>The key players in the Pulmonary Arterial Hypertension market include United Therapeutics Corporation, Liquidia Technologies, Reata Pharmaceuticals, Altavant Sciences, Acceleron Pharma, PhaseBio Pharmaceuticals, Complexa, Arena Pharmaceuticals, Johnson & Johnson, GlaxoSmithKline Pharmaceuticals/Gilead Sciences Inc., Bayer AG, Pfizer, Bellerophon Pulse Technologies, and many others.<br><br>For more information visit:<br>https://www.delveinsight.com/report-store/pulmonary-arterial-hypertension-pah-market#infographics<br><br><br>#bloodpressure<br>#bp <br>#Pulmonaryarterialhypertension<br>#hypertension<br><br>
E N D